Sarepta Therapeutics, Inc. Faces Class Action Securities Lawsuit

Strategic Insights -

Sarepta Therapeutics, Inc.'s (NASDAQ: SRPT) investors who suffered losses may be eligible to recover their losses under the federal securities laws. A class action lawsuit was filed against the company, alleging that it made false statements and concealed significant safety risks associated with its prescription gene therapy, ELEVIDYS. The lawsuit claims that the company's positive statements about the therapy were misleading, and it concealed the severity of adverse events related to its treatment.

Key Takeaways:

  • A class action lawsuit was filed against Sarepta Therapeutics, Inc. alleging securities fraud between June 22, 2023, and June 24, 2025.
  • The lawsuit claims that the company made false statements and concealed significant safety risks associated with its prescription gene therapy, ELEVIDYS.
  • The alleged misconduct includes concealing that ELEVIDYS posed significant safety risks, failed to detect severe side effects, and halted recruitment and dosing in its trials.
  • The lawsuit seeks to recover losses of shareholders who were adversely affected by the alleged securities fraud.
  • Levi & Korsinsky LLP, a nationally-recognized securities litigation firm, is representing the investors in the lawsuit.
  • The law firm has secured hundreds of millions of dollars for aggrieved shareholders and has a track record of winning high-stakes cases.

Statistics:

  • The lawsuit was filed between June 22, 2023, and June 24, 2025.
  • The relevant time frame for the alleged securities fraud is from June 22, 2023, to June 24, 2025.
  • The lawsuit is seeking to recover losses of shareholders who were adversely affected by the alleged securities fraud.
  • Levi & Korsinsky LLP has secured hundreds of millions of dollars for aggrieved shareholders over the past 20 years.

Sources:

  • News release from Newsfile Corp., dated August 4, 2025: https://www.newsfilecorp.com/release/261135
  • Sarepta Therapeutics, Inc.'s (NASDAQ: SRPT) press release, dated August 4, 2025.